Diagnosis and management of AML in adults

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the...

Descripción completa

Detalles Bibliográficos
Autores: Döhner, Hartmut|||0000-0003-2116-5536, Wei, Andrew H.|||0000-0002-7514-3298, Appelbaum, Frederick, Craddock, Charles|||0000-0001-5041-6678, DiNardo, Courtney D.|||0000-0001-9003-0390, Dombret, Hervé, Ebert, Benjamin L.|||0000-0003-0197-5451, Fenaux, Pierre, Godley, Lucy A., Hasserjian, Robert P.|||0000-0002-7753-0697, Larson, Richard A.|||0000-0001-9168-3203, Levine, Ross L., Miyazaki, Yasushi, Niederwieser, Dietger|||0000-0002-4737-1103, Ossenkoppele, Gert, Röllig, Christoph, Sierra, Jorge|||0000-0002-7966-0356, Stein, Eytan M., Tallman, Martin S., Tien, Hwei-Fang F., Wang, Jianxiang|||0000-0001-9437-9151, Wierzbowska, Agnieszka|||0000-0001-7909-457X, Löwenberg, Bob|||0000-0001-8982-5217
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:280875
Acceso en línea:https://ddd.uab.cat/record/280875
https://dx.doi.org/urn:doi:10.1182/blood.2022016867
Access Level:acceso abierto
Palabra clave:Adult
Antineoplastic Agents
Humans
Leukemia, Myeloid, Acute
Mutation
Neoplasm, Residual
Nucleophosmin
Prognosis
Proto-Oncogene Proteins c-bcl-2
Descripción
Sumario:The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Similares en LA Referencia